BullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease. BullFrog AI Holdings, Inc. was founded in 2017 and is based in Gaithersburg, Maryland.
P/B ratio for Bullfrog AI Holdings, Inc. Common Stock (BFRG)
P/B ratio as of 2023: 7.61
According to Bullfrog AI Holdings, Inc. Common Stock's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 7.61. At the end of 2022 the company had a P/B ratio of -12.94.
P/B ratio history for Bullfrog AI Holdings, Inc. Common Stock from 2020 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 7.61 |
| 2022 | -12.94 |
| 2021 | -36.40 |
| 2020 | -67.95 |